Comments
Drug-maker Lupin is in the process of drawing up a road map for bio-similar products in the European market. The company had recently made foray into Japan through a joint venture for its bio-similar products.
Lupin would partner with companies for some European markets, where it does not have a presence, Chief Executive Vinita Gupta said. Bio-similars are follow-on products of biological drugs.
Profit up 55%For the three months ended September 30, Lupin’s net profit grew 55 per cent to ₹630 crore against ₹406 crore in the corresponding quarter last year. Net sales grew 18 per cent to ₹3,116 crore during the quarter (₹2,631 crore). Lupin’s US sales increased 21 per cent to $202 million in the quarter. On Tuesday, its scrip closed down 2.61 per cent at ₹1357.65.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.